Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran AND Alborz Office of Universal Scientific Education and Research Network (USERN), Alborz University of Medical Sciences, Karaj, Iran.
Department of Allergy and Clinical Immunology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Allergy Asthma Immunol. 2021 Aug 7;20(4):384-393.
Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness.
新型冠状病毒病（COVID-19）是一个全球性的新兴问题，已经影响了全球许多人。到目前为止，许多研究旨在开发针对 COVID-19 的治疗方法。孟鲁司特（MK）是一种安全的哮喘控制药物，被认为是严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的潜在抗病毒药物。本综述采用系统方法调查了关于将 MK 作为 COVID-19 治疗或预防药物一部分使用的报告。在 PubMed、Web of Science 和 Scopus 数据库中进行了搜索，共检索到 35 项研究，其中包含 MK 对 SARS-CoV-2 的影响。最终，MK 似乎值得作为一种辅助治疗和预防 SARS-CoV-2 的药物。然而，需要更多的临床试验来准确研究其疗效。
